“In a study appearing in the September 20 issue of JAMA, Bradley D. Stein, M.D., Ph.D., of RAND Corporation, Pittsburgh, and colleagues examined patient censuses of buprenorphine prescribers to determine whether patient limits have been a barrier to buprenorphine treatment.
The researchers used a database that contains pharmacy retail transactions from more than 80 percent of pharmacies nationwide, including high-volume national chain pharmacies, resulting in information on approximately 90 percent of prescriptions filled at retail pharmacies in the United States. Data from 7 states with the most buprenorphine-waivered physicians (California, Florida, Massachusetts, Michigan, New York, Pennsylvania, Texas) were analyzed.
The study included 3,234 buprenorphine prescribers with 245,016 patients receiving a new prescription of buprenorphine from 2010-2013. The authors found that the monthly patient censuses for buprenorphine-prescribing physicians were substantially below patient limits; more than 20 percent treated 3 or fewer patients, and fewer than 10 percent treated more than 75 patients. The median treatment duration (53 days) was lower than expected given clinical recommendations of maintenance treatment for up to 12 months and evidence linking longer treatment to better outcomes.”
Read more at: http://www.medicalnewstoday.com/releases/313015.php
See related article available at: http://medicalresearch.com/author-interviews/fewer-physicians-than-anticipated-treat-opioid-use-disorder-with-buprenorphine/28219/
Source: MedicalNewsToday.com – September 21, 2016